Kabra Drugs Ltd

Board composition

• Board as of 12 Aug 2026 includes Nanjappan Aravind (MD & Chair) and four independent directors.
• Executive Directors: Kuniamuthur Nanjappan Anand; Independent Directors: Nikita Sinha, Ritu Tiwari, Moonam Kapoor.

Audit Committee

• Audit Committee Chair: Nikita Sinha (Independent).
• Members: Kuniamuthur Anand (Executive Director); Moonam Kapoor (Independent).

Nomination & Remuneration

• Nomination & Remuneration Committee Chair: Ritu Tiwari (Independent).
• Members: Nikita Sinha; Moonam Kapoor (Independent).

Stakeholders Relationship

• Stakeholders Relationship Committee Chair: Moonam Kapoor (Independent).
• Members: Nikita Sinha, Ritu Tiwari (Independent).

Resigning director

• Name and designation: Ms. Anand Anitha, Director.
• Directorship type: Director (no independent/non-exec categorization stated).
• Date of resignation: 12 August 2026.
• Reason for resignation: Personal reasons; no other material reasons disclosed.
• Listed entity directorships held: No.
• Board committee memberships held: No.
• Regulatory/stockholder approval: not specified as required.
• Impact on board/committee composition: no explicit changes disclosed.

Regulation 32 non-applicable

• Regulation 32 not applicable; no share issuance through any mode in the quarter.
• No funds were raised; hence no deviation, variation, or utilisation status to report.

Financial highlights

• Revenue from operations: ₹4,621.68 lakh in Q1 FY27; QoQ +30.5% vs ₹3,540.60 lakh.
• Total income: ₹4,629.33 lakh in Q1 FY27; QoQ up vs ₹3,551.91 lakh.
• Purchases of stock-in-trade: ₹4,903.20 lakh.
• Changes in inventories: (₹603.00) lakh.
• Employee benefits expense: ₹23.72 lakh.
• Finance costs: ₹0.53 lakh.
• Depreciation & amortization: ₹2.06 lakh.
• Other expenses: ₹18.81 lakh.
• Total expenses: ₹4,345.32 lakh.
• Profit before tax: ₹284.01 lakh.
• Tax: ₹71.71 lakh.
• Net profit after tax: ₹212.30 lakh.
• EPS (Basic/Diluted): ₹0.90.
• Single segment; no segment reporting.

Financial results and approvals

• Unaudited standalone Q1 FY2026-27 results approved by Board on 12 Aug 2026.
• Revenue from operations ₹4,621.68 lakh; total income ₹4,629.33 lakh.
• Net profit after tax ₹212.30 lakh; basic/diluted EPS ₹0.90.
• Audit Committee reviewed; results approved by Board; limited review by statutory auditors.
• Interim results prepared under Ind AS 34; single segment; no subsidiary.
• There were no exceptional or extraordinary items for the period.
• Company identity noted as Aanjaay Industries Limited (formerly Kabra Drugs Limited).

Reg 74(5) compliance

• Certificate confirms Reg 74(5) compliance for the reporting period.

Name change details

• Name changed from Kabra Drugs Limited to Aanjaay Industries Limited with effect from July 06, 2026.
• Fresh Certificate of Incorporation issued by the MCA for the name change.
• Shareholders approved the name change and alteration of the Memorandum and Articles of Association.
• Updated MOA/AOA will be available on the company's website.

LOI for project

• Kabra Drugs received an LOI from Chhattisgarh for a ₹200 crore manufacturing project.
• The proposed facility will be located at Nava Raipur Pharma Park.
• The project covers pharmaceutical manufacturing and related healthcare manufacturing activities.

Project impact

• The company expects the project to expand manufacturing footprint and production capacity.
• The project is expected to create about 250 direct and indirect jobs.
• The investment remains subject to definitive agreements, approvals, and sanctions.

Strategic outlook

• Management said the project supports long-term growth and strengthens its pharmaceutical presence.
• The company expects to benefit from applicable state incentives and support mechanisms.